Pioglitazone on Heart Failure in Type-2 Diabetes Mellitus Participants

Heart Failure With Preserved Ejection Fraction Clinical Trial

— PIOHF  

Official title:

Pioglitazone, Lipotoxicity, and Heart Failure With Preserved Ejection Fraction (HFpEF)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05838287
• Other study ID #: HSC20220916H
• Status: Recruiting
• Phase: Phase 4
• Start date: July 10, 2023
• Est. completion date: January 2029

Study information

• Verified date: July 2023
• Source: The University of Texas Health Science Center at San Antonio
• Contact: Sivaram Neppala, MD
• Phone: 210-358-7200
• Email: neppalas[@]uthscsa.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Our goal of the study is to learn the effects of the diabetes medication named Pioglitazone, in type-2 diabetic obese participants with Heart failure. The main question it aims to answer are:

1. To demonstrate that impaired mitochondrial function leading to reduced ATP generation plays a key pathophysiologic role in the development of heart failure with preserved ejection fraction (HFpEF) in obese type 2 diabetic (T2D) individuals.

2. To demonstrate that pioglitazone, improves diastolic (as well as systolic) function by improving myocardial insulin sensitivity and by reducing both myocardial and epicardial fat content.

Description:

Either Pioglitazone or Placebo Pioglitazone will be administered during this study in this Type 2 Diabetic population with Heart Failure to examine if there are any beneficial effects on diastolic and systolic function.

Myocardial blood flow (MBF) is measured using a PET scan, then participants will be randomized to pioglitazone or a placebo to examine the effects of the study drug on the effects on the systolic and diastolic function of the heart. In addition, myocardial insulin sensitivity change will be measured as well as myocardial fat content. The ratio of ATP: PCr will also be measured.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 78
• Est. completion date: January 2029
• Est. primary completion date: April 2028
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 30 Years to 70 Years

Eligibility

Inclusion Criteria:

1. Provision of signed and dated informed consent form

2. Stated willingness to comply with all study procedures and availability for the duration of the study

3. Male or female, aged 30-70 years

4. Body Mass Index (BMI) of 27.5-40kg/m²

5. HbA1c of 6.5 to 10%

6. Blood pressure of less than or equal to 145/65mmHg

7. eGFR greater than 45 ml/min/1.73m²

8. Subject must have HFpEF (EF > 50% by ECHO screening)

9. NYHA class II-III heart failure

10. Only T2D patients treated with diet/exercise, metformin, sulfonylurea, metformin/SU, DPP4i or insulin will be studied.

11. For females of reproductive potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation and for an additional [4 weeks] after the end of study participation.

12. For males of reproductive potential: use of condoms or other methods to ensure effective contraception with partner.

Exclusion Criteria:

1. Subjects with history of osteoporosis or proliferative diabetic retinopathy

2. Subjects with Heart failure due to restrictive or infiltrative cardiomyopathy, active myocarditis, constrictive pericarditis, severe valvular heart disease, etc. will be excluded

3. Patients with symptomatic coronary artery disease.

4. Subjects with significant change in diuretic management during the month prior to screening (defined by doubling of diuretic dose, or addition of another HF medication).

5. Subjects treated with a GLP-1 RA or thiazolidinedione.

6. Subjects treated with a SGLT2i

7. Pregnancy or lactation

8. Known allergic reactions to components of the study interventions.

9. Any metal plates, parts, screws, shrapnel, pins in body, or cardiac (heart) pacemaker

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes Mellitus, Type 2
• Heart Failure
• Heart Failure With Preserved Ejection Fraction
• Type 2 Diabetes Mellitus in Obese

Intervention

Drug:
• Pioglitazone
Participants will be taking Pioglitazone tablets 1/day for 24 weeks.
• Placebo
Placebo for Pioglitazone

Locations

Country	Name	City	State
United States	Texas Diabetes Institute/UH	San Antonio	Texas

Sponsors (1)

Lead Sponsor	Collaborator
The University of Texas Health Science Center at San Antonio

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Systolic function	Measurement of change in systolic function of the heart using cardiac MRI	Baseline and 6-months post treatment (approximately 24 weeks)
Primary	Change in Diastolic function	Measurement of change in diastolic function of the heart using cardiac MRI	Baseline and 6-months post treatment (approximately 24 weeks)
Secondary	Myocardial insulin sensitivity	Measurement of change in Free Plasma Glucose (FPG) in blood plasma	Baseline and 6-months post treatment (approximately 24 weeks)
Secondary	Myocardial fat content	Measurement of change in myocardial fat content	Baseline and 6-months post treatment (approximately 24 weeks)
Secondary	PCr:ATP ratio	Measurement of change in PCr:ATP ratio	Baseline and 6-months post treatment (approximately 24 weeks)